RayKnowChina Research Map
Shortlist0

RecruitingNasopharyngeal carcinomaPhase 2

Registered title, quoted from ClinicalTrials.gov

Envafolimab Plus Chemoradiotherapy for Locally Advanced NPC, a Prospective, Single Armed Phase II Trial.

An open trial on nasopharyngeal carcinoma, registered on ClinicalTrials.gov. Led by Sun Yat-sen University Cancer Center; 0 other hospitals on this site are listed as study sites.

Status, phase and start date as registered on ClinicalTrials.gov on 8 Nov 2026; the registry may have changed since. Whether someone can take part is decided by the study team. Not medical advice.

The study team’s contact details are on the registry record. This site does not pass on enquiries.

Hospitals in mainland China listed for this trial 1

Hospitals on this site that the registry record names as lead sponsor or study site, where the site is open. Lead sponsor first, then study sites A–Z.

  1. Lead (inferred)Sun Yat-sen University Cancer Center中山大学肿瘤防治中心GuangzhouHospital page

The record may name more sites, including outside mainland China, and sites can open or close during a trial. Full list of sites on ClinicalTrials.gov

Source: ClinicalTrials.gov record NCT05397769, read on 8 Nov 2026; hospital names matched to this site’s hospital list. How names are matched

Checklist for this trial 7

Only the points this trial’s record answers definitely: the registered age and sex, and criteria lines that state a number, score, stage or named test, quoted word for word. Tick a point once it has been compared with the medical records.

Show the checklist (7 points)Hide the checklist
  1. 18 years to 65 years; sex: all

    Registered eligibility fields

  2. histologically confirmed non-keratinizing carcinoma (WHO type II or III) of nasal pharynx

    Inclusion criterion 2

  3. stage III-IVa (AJCC/UICC 8th ), untreated NPC patients

    Inclusion criterion 3

  4. ECOG 0-1

    Inclusion criterion 1

  5. ALT≤ 1.5 upper limit of normal (ULN), AST≤ 1.5ULN and bilirubin ≤ 1.5ULN

    Inclusion criterion 5

    creatinine<1.5×ULN

    Inclusion criterion 6

  6. HIV (+)

    Exclusion criterion 5

    HBsAg (+) and HBV DNA >1×10E3 copiers /mL

    Exclusion criterion 15

    HCV (+) unless HCV RNA PCR(-)

    Exclusion criterion 16

  7. pregnant or lactating women, or women of childbearing age without birth control

    Exclusion criterion 4

Ticks stay on this page; they are not saved or sent. Meeting every point is not enough: the study team decides after its own screening. Lines that need the team’s judgement, such as “sufficient organ function”, are not in this list; they are in the full criteria below. Not stated definitely in this record: earlier treatment; scans and measurable lesions.

Questions to ask the study team

Picked from the record by fixed keyword rules (not by AI, not checked by hand) and quoted from ClinicalTrials.gov, NCT05397769, read on 10 Nov 2026.

Registered criteria

Quoted as registered on ClinicalTrials.gov, in English, read on 10 Nov 2026. This site has not checked, shortened or translated them. Meeting the written criteria is not enough: the study team decides after its own screening.

Inclusion Criteria:

  • ECOG 0-1
  • histologically confirmed non-keratinizing carcinoma (WHO type II or III) of nasal pharynx
  • stage III-IVa (AJCC/UICC 8th ), untreated NPC patients
  • NE≥ 1.5×10E9/L, HGB ≥ 100g/L and PLT ≥100×10E9/L
  • ALT≤ 1.5 upper limit of normal (ULN), AST≤ 1.5ULN and bilirubin ≤ 1.5ULN
  • creatinine<1.5×ULN

Exclusion Criteria:

  • recurrent or metastatic NPC patients
  • histologically confirmed keratinizing carcinoma (WHO type I) of nasal pharynx
  • already received radiation or chemotherapy
  • pregnant or lactating women, or women of childbearing age without birth control
  • HIV (+)
  • had other cancers before
  • used immune checkpoint inhibitor(CTLA-4、PD-1、PD-L1 etc.) before
  • complications requiring long-term treatment with immunosuppressive drugs or systemic or local use of corticosteroids with immunosuppressive dose
  • with immune deficiency diseases, or a history of organ transplantation (including but not limited to: interstitial pneumonia, uveitis, enteritis, hepatitis, hypophysitis, nephritis, hyperthyroidism and hypothyroidism; Patients with vitiligo or asthma in childhood who have completely relieved and do not need any intervention after adulthood can be included; Asthma requiring medical intervention with bronchodilators cannot be included)
  • use of massive dose of glucocorticoids within 4 weeks before enrollment
  • laboratory test values do not meet relevant standards within 7 days before enrollment
  • significantly lower functions of heart, liver, lung, kidney and bone marrow
  • serious or uncontrolled medical diseases or infections
  • participating other clinical trial in the same time
  • HBsAg (+) and HBV DNA >1×10E3 copiers /mL
  • HCV (+) unless HCV RNA PCR(-)
  • with any other treatment contraindications

Quoted from ClinicalTrials.gov, NCT05397769, participation criteria. Read on 10 Nov 2026.

Where this information comes from

The registry record

ClinicalTrials.gov (US National Library of Medicine), record NCT05397769, read on 8 Nov 2026. A trial has a page here while its overall status is recruiting, not yet recruiting or enrolling by invitation and at least one listed hospital’s site is open. Trials registered only in China’s own registry (ChiCTR) are not included.

Diseases and hospitals

The trial is listed under a disease when this site’s ClinicalTrials.gov search for that disease in China returns it. Sponsor and site names in the record are matched to this site’s hospital list (ROR identifiers, checked aliases). Definitions

What is left out

Names of investigators and contact persons in the record, and anything not in the record. The title and criteria are quoted from the record.

Suggest a correctionClinicalTrials.gov NCT05397769